Hadassah, provider of "Regulatory-Ready" pluripotent clinical-grade stem cell banks

Tannenbaum, Shelly E.; Singer, Orna; Gil, Yaniv; Berman-Zaken, Yael; Ilouz, Nili; Khaner, Hanita; Haimov, Miriam; Reubinoff, Benjamin

doi:10.1016/j.scr.2019.101670

Cited by 5 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in accordance with the previous report that hUC can be used as a source for vascular cell bank [ 16 ]. It is worth mentioning that, besides the establishment of xeno-free culture system for both WJ-MSCs and HUVECs, our findings fulfill the attempt to establish therapeutic applicable cell bank [ 32 – 36 ] by offering a possibility to set up “two-in-one” (two cell types in one sample) autogenic cell bank.…”

Section: Discussionmentioning

confidence: 53%

A Xeno-Free Strategy for Derivation of Human Umbilical Vein Endothelial Cells and Wharton’s Jelly Derived Mesenchymal Stromal Cells: A Feasibility Study toward Personal Cell and Vascular Based Therapy

Kunkanjanawan¹,

Kunkanjanawan²,

Khemarangsan³

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

Coimplantation of endothelial cells (ECs) and mesenchymal stromal cells (MSCs) into the transplantation site could be a feasible option to achieve a sufficient level of graft-host vascularization. To find a suitable source of tissue that provides a large number of high-quality ECs and MSCs suited for future clinical application, we developed a simplified xeno-free strategy for isolation of human umbilical vein endothelial cells (HUVECs) and Wharton’s jelly-derived mesenchymal stromal cells (WJ-MSCs) from the same umbilical cord. We also assessed whether the coculture of HUVECs and WJ-MSCs derived from the same umbilical cord (autogenic cell source) or from different umbilical cords (allogenic cell sources) had an impact on in vitro angiogenic capacity. We found that HUVECs grown in 5 ng/ml epidermal growth factor (EGF) supplemented xeno-free condition showed higher proliferation potential compared to other conditions. HUVECs and WJ-MSCs obtained from this technic show an endothelial lineage (CD31 and von Willebrand factor) and MSC (CD73, CD90, and CD105) immunophenotype characteristic with high purity, respectively. It was also found that only the coculture of HUVEC/WJ-MSC, but not HUVEC or WJ-MSC mono-culture, provides a positive effect on vessel-like structure (VLS) formation, in vitro. Further investigations are needed to clarify the pros and cons of using autogenic or allogenic source of EC/MSC in tissue engineering applications. To the best of our knowledge, this study offers a simple, but reliable, xeno-free strategy to establish ECs and MSCs from the same umbilical cord, a new opportunity to facilitate the development of personal cell-based therapy.

show abstract

Section: Discussionmentioning

confidence: 53%

A Xeno-Free Strategy for Derivation of Human Umbilical Vein Endothelial Cells and Wharton’s Jelly Derived Mesenchymal Stromal Cells: A Feasibility Study toward Personal Cell and Vascular Based Therapy

Kunkanjanawan¹,

Kunkanjanawan²,

Khemarangsan³

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…The majority of hESC clinical trials to date have been conducted with earlier non-xeno free cell lines (H1, MA09, and I6). 75 More recently, completely xeno-free hESC have been used for Phase I/II clinical trials such as the Hadassah hESC cell lines (HAD-C 100, 102, 106) for retinal degeneration and amyotrophic lateral sclerosis ( 73 ; clinicaltrials.gov). Clinical trials specific to ES-MSC are limited.…”

Section: Translation Of Esc-derived Chondroprogenitors To the Clinicmentioning

confidence: 99%

Challenges Facing the Translation of Embryonic Stem Cell Therapy for the Treatment of Cartilage Lesions

Grogan

Kopcow

D’Lima

2022

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Osteoarthritis is a common disease resulting in significant disability without approved disease-modifying treatment (other than total joint replacement). Stem cell-based therapy is being actively explored for the repair of cartilage lesions in the treatment and prevention of osteoarthritis. Embryonic stem cells are a very attractive source as they address many of the limitations inherent in autologous stem cells, such as variability in function and limited expansion. Over the past 20 years, there has been widespread interest in differentiating ESC into mesenchymal stem cells and chondroprogenitors with successful in vitro, ex vivo, and early animal studies. However, to date, none have progressed to clinical trials. In this review, we compare and contrast the various approaches to differentiating ESC; and discuss the benefits and drawbacks of each approach. Approaches relying on spontaneous differentiation are simpler but not as efficient as more targeted approaches. Methods replicating developmental biology are more efficient and reproducible but involve many steps in a complicated process. The small-molecule approach, arguably, combines the advantages of the above two methods because of the relative efficiency, reproducibility, and simplicity. To better understand the reasons for lack of progression to clinical applications, we explore technical, scientific, clinical, and regulatory challenges that remain to be overcome to achieve success in clinical applications.

show abstract

“…However, implementation of rapid screening for genetic stability could enable early abandonment of WCB manufacture due to the most likely QC problem of expansion of genetic variants. This approach has been tested in a number of centers including the UK Stem Cell Bank (UKSCB) and has been published by the Hadassah Medical Centre 33 . It addresses a key element of COGs reduction for cell therapies which is to optimize utility of capacity 22 .…”

Section: Crucial Considerationmentioning

confidence: 99%

Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies

et al. 2022

View full text Add to dashboard Cite

This report summarizes key issues contributing to the cost of preparing human pluripotent stem cell lines for use in cell therapy manufacturing based on discussion between stem cell banking experts from ten countries at a workshop session on 'cost of goods' for human pluripotent stem cell banking organized by the International Stem Cell Banking Initiative (ISCBI) held at the Korea National Institutes of Health in Korea (25 th September 2019). In this report, we also build on the workshop discussion and highlight and discuss the full range of costs and unexpected challenges on resources for the delivery of stocks of hPSCs suitable for use as starting materials in the manufacture of stem cell-based medicines. The experiences of global leaders from different national resource centers highlight issues to consider in cost management and the possibilities for reducing costs while moving into the clinical application stage.

show abstract

Hadassah, provider of "Regulatory-Ready" pluripotent clinical-grade stem cell banks

Cited by 5 publications

References 3 publications

A Xeno-Free Strategy for Derivation of Human Umbilical Vein Endothelial Cells and Wharton’s Jelly Derived Mesenchymal Stromal Cells: A Feasibility Study toward Personal Cell and Vascular Based Therapy

A Xeno-Free Strategy for Derivation of Human Umbilical Vein Endothelial Cells and Wharton’s Jelly Derived Mesenchymal Stromal Cells: A Feasibility Study toward Personal Cell and Vascular Based Therapy

Challenges Facing the Translation of Embryonic Stem Cell Therapy for the Treatment of Cartilage Lesions

Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies

Contact Info

Product

Resources

About